Skip to Main Content

Hobart W. Harris


Gastrointestinal surgeon

Dr. Hobart W. Harris is an expert in treating surgical infections and diseases of the pancreas and biliary system. He cares for patients with complicated and often life-threatening conditions in the Complex Abdominal Surgery Program. His areas of expertise include pancreas and bile duct cancer, acute and chronic pancreatitis, islet cell transplantation for pancreatitis, gallstone disease, intra-abdominal sepsis and serious infections of the skin and soft tissue.

Harris research focuses on surgical infections, innate immunity and inflammatory diseases of the pancreas.

Harris earned his undergraduate and medical degrees, as well as a master of public health degree, at Harvard University. He completed a residency in surgery at UCSF, followed by a fellowship in hepatobiliary surgery at the University of Hong Kong, Queen Mary Hospital. He joined UCSF in 1994.

Harris is a fellow of the American College of Surgeons. He is a member of numerous surgical and scientific societies, including the American Surgical Association.

  • Education

    Harvard University School of Medicine, 1983

  • Residencies

    UCSF Medical Center, General Surgery, 1993

  • Fellowships

    University of Hong Kong, Heptobiliary Surgery, 1994

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title


  • Languages


Where I see patients (3)

    My reviews


    Overall Experience
    87 Ratings
    Explained things in a way that was easy to understand
    87 Ratings
    Did the doctor pay attention to your concerns
    87 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    84 Ratings
    Knew the important information about your medical history
    87 Ratings
    The provider showed respect for what you had to say
    87 Ratings
    The provider spent enough time with me
    87 Ratings

    Selected research

    Decorative Caduceus

    Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

    The primary endpoint of the trial is the occurrence of incisional hernia in each treatment group (Phasix™ Mesh or Control Group)